Blog
RSS FeedPosted by Michael Wonder on 19 Apr 2021
Seagen and Astellas announce U.S. FDA acceptance of two supplemental biologics license applications for Padcev (enfortumab vedotin-ejfv) in locally advanced or metastatic urothelial cancer
19 April 2021 - Australia and Canada regulators will review applications as part of FDA’s Project Orbis. ...
Posted by Michael Wonder on 16 Apr 2021
FDA revokes emergency use authorisation for monoclonal antibody bamlanivimab
16 April 2021 - Alternative monoclonal antibody therapies authorised to treat patients with COVID-19 remain available. ...
Posted by Michael Wonder on 16 Apr 2021
FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and oesophageal adenocarcinoma
16 April 2021 - Today, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced ...
Posted by Michael Wonder on 16 Apr 2021
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
16 April 2021 - Final step in Lilly's planned transition to provide only bamlanivimab and etesevimab together in the U.S. ...
Posted by Michael Wonder on 16 Apr 2021
Mayne Pharma and Mithra announce FDA approval of new oral contraceptive Estelle
15 April 2021 - Mayne Pharma Group and Mithra Pharmaceuticals are very pleased to announce that the US FDA has approved ...
Posted by Michael Wonder on 15 Apr 2021
White House expands list of potential FDA Commissioners
14 April 2021 - Asian-American and Black doctors on short list of nominees to lead agency. ...
Posted by Michael Wonder on 15 Apr 2021
Perimeter Medical Imaging AI receives U.S. FDA breakthrough device designation for its optical coherence tomography imaging system with ImgAssist AI
15 April 2021 - New designation provides potential pathway to expedite adoption of Perimeter's transformative medical imaging technology combined with artificial ...
Posted by Michael Wonder on 15 Apr 2021
FibroGen receives rare paediatric disease designation from the U.S. FDA for pamrevlumab for the treatment of Duchenne muscular dystrophy
15 April 2021 - FibroGen announced that the U.S. FDA has granted rare paediatric disease designation for the company’s anti-CTGF antibody, ...
Posted by Michael Wonder on 15 Apr 2021
FDA wants more data on promising ALS drug, frustrating patients seeking faster access
15 April 2020 - People living with amyotrophic lateral sclerosis, or ALS, in the U.S. will have to wait longer ...
Posted by Michael Wonder on 14 Apr 2021
PhRMA's three part approach to build a better health care system
13 April 2021 - Our plan is based on three key pillars: ending the pandemic and building a more resilient system, ...
Posted by Michael Wonder on 14 Apr 2021
Moleculin awarded new rare paediatric disease designation from U.S. FDA for WP1066 for the treatment of ependymoma
14 April 2021 - Moleculin Biotech announced today that the U.S. FDA has granted rare paediatric disease designation to its ...
Posted by Michael Wonder on 13 Apr 2021
U.S. FDA to scrutinise vaccine design behind COVID-19 shots linked to blood clots
13 April 2021 - With two COVID-19 vaccines now under scrutiny for possible links to very rare cases of blood ...
Posted by Michael Wonder on 13 Apr 2021
Atossa Therapeutics announces ovarian cancer patient has begun treatment with oral endoxifen under FDA’s Expanded Access Pathway
13 April 2021 - Atossa Therapeutics today announced that an ovarian cancer patient has begun treatment with Atossa’s proprietary oral endoxifen. ...
Posted by Michael Wonder on 13 Apr 2021
FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer
13 April 2021 - Today the Food and Drug Administration granted accelerated approval to sacituzumab govitecan (Trodelvy, Immunomedics) for patients ...
Posted by Michael Wonder on 13 Apr 2021
vTv Therapeutics receives FDA breakthrough therapy designation for TTP399 for the treatment of type 1 diabetes
13 April 2021 - Designation offers potential for expedited development pathway and reinforces TTP399’s potential to provide a substantial clinical benefit. ...